Jupiter Topco LLC Takes Position in Biohaven Ltd. $BHVN

Jupiter Topco LLC acquired a new position in Biohaven Ltd. (NYSE:BHVN) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,584,675 shares of the company’s stock, valued at approximately $127,852,000. Jupiter Topco LLC owned 0.06% of Biohaven as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. PNC Financial Services Group Inc. raised its stake in Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after purchasing an additional 1,268 shares during the period. IFP Advisors Inc boosted its stake in Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after purchasing an additional 1,450 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Biohaven by 178.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after purchasing an additional 2,583 shares during the period. Arax Advisory Partners grew its holdings in Biohaven by 943.3% during the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after buying an additional 4,443 shares in the last quarter. Finally, Essential Partners LLC grew its holdings in Biohaven by 31.7% during the 1st quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after buying an additional 2,169 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven News Roundup

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Major epilepsy licensing agreement: Biohaven licensed its Kv7 ion-channel platform, including lead epilepsy candidate opakalim, to SK Biopharmaceuticals in a deal potentially worth up to $795 million. The agreement includes upfront and milestone payments, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
• Positive Sentiment: Validation and potential funding: Opakalim is in Phase 2/3 development for focal epilepsy, and the partnership gives Biohaven a potential source of non-dilutive capital while adding a global development and commercialization partner. The deal also increased investor focus on the company’s broader pipeline. Biohaven and SK Biopharmaceuticals licensing announcement
• Positive Sentiment: Favorable trade-secret ruling: A federal court confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, formalizing a $4 million award to Biohaven and Yale University. The ruling removes uncertainty around the case and provides a financial recovery for Biohaven. Biohaven trade-secret lawsuit ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026. The licensing deal improves the commercial outlook, but milestone payments and royalties remain dependent on development, regulatory and sales outcomes. BHVN stock and upcoming trial readout

Biohaven Stock Up 19.1%

NYSE BHVN opened at $17.12 on Thursday. The stock has a 50 day moving average price of $14.74 and a 200-day moving average price of $11.83. Biohaven Ltd. has a one year low of $7.48 and a one year high of $18.57. The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. The company has a market capitalization of $2.59 billion, a P/E ratio of -3.69 and a beta of 1.26.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). As a group, equities analysts predict that Biohaven Ltd. will post -3.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BHVN shares. Bank of America reiterated an “underperform” rating and set a $11.00 price objective (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Needham & Company LLC set a $11.00 price target on shares of Biohaven in a report on Monday, June 29th. TD Cowen reiterated a “buy” rating on shares of Biohaven in a research note on Wednesday. Finally, Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.94.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.